Methanesulfonamide, N-[[1-[6-(trifluoromethyl)-4-quinazolinyl]-3-piperidinyl]methyl]-;SRI-37330;SRI 37330,SRI37330;SRI-37330, 10 mM in DMSO;N-((1-(6-(Trifluoromethyl)quinazolin-4-yl)piperidin-3-yl)methyl)methanesulfonamide
SRI-37330 is an orally active TXNIP inhibitor that reduces glucagon secretion and action and blocks hepatic glucose output; it can be used in the research of obesity and diabetes.